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Abstract 
Non-alcoholic fatty liver disease (NAFLD) affects 25% of adults and at present no licensed 
medication has been approved. Despite its complex patho-physiology, dietary strategies 
aiming at delaying or preventing NAFLD have taken a reductionist approach, examining the 
impact of single components. Accumulating evidence suggests that n-3 LC-PUFAs are 
efficacious in regulating lipogenesis and fatty acid oxidation. In addition, plant derived 
flavonoids are also emerging as a dietary strategy for NAFLD prevention, with efficacy 
attributed to their insulin sensitising and indirect antioxidant effects. Based on knowledge of 
their complementary molecular targets, we aimed to demonstrate that the combination of n-3 
LC-PUFA (n-3) and flavan-3-ols (FLAV) prevents NAFLD.  In a high-fat high-fructose 
(HF/HFr) fed C57Bl/6J mouse model, the independent and interactive impact of n-3 and 
FLAV on histologically defined NAFLD, insulin sensitivity, weight gain, intestinal and hepatic 
gene expression, intestinal bile acids were examined. Only the combination of FLAV and n-3 
(FLAVn-3) prevented steatosis as evidenced by a strong reduction in hepatocyte ballooning. 
Whilst FLAV reduced body (-28-30%), adipose tissue (-45-50%) weights and serum insulin (-
22-25%) as observed following an intra-peritoneal glucose tolerance test, n-3 downregulated 
the expression of Srebf1 and the lipogenic genes (Acaca, Fasn). Significant impacts of 
interventions on intestinal bile acid metabolism, farnesoid X receptor (Fxr) signaling in the 
intestine and liver, and hepatic expression of fatty acid transporters (Fabp4, Vldlr, Cd36) 
were also evident. FLAVn-3 may be a novel intervention for NAFLD. Future research should 
aim to demonstrate its efficacy in the prevention and treatment of human NAFLD.   
 
Keywords: fish oil; flavonoids; Srebp-1c, bile acids, NASH. 
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1. INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) associated with obesity, has a global prevalence 
of 25% in adults [1].  It is a spectrum of progressive liver damage ranging from benign 
steatosis, to non-alcoholic steatohepatitis (NASH) characterised by necro-inflammation and 
hepatocyte injury [2]. In about 10% of patients, NASH leads to fibrosis and cirrhosis and an 
increased risk of liver failure and hepatocellular carcinoma [3]. Increased CVD incidence is 
the most prevalent clinical feature of NAFLD [4].  
The pathogenic progression of NAFLD is characterised by a loss of insulin sensitivity and 
hepatocyte accumulation of fat, which can induce lipotoxicity through oxidative stress and a 
pro-inflammatory state, leading to cellular damage [5]. Emerging evidence indicates that 
alterations in bile acid metabolism and associated farnesoid X nuclear receptor (Fxr) 
signalling also contribute to the development of NAFLD and obesity [6].   
At present no licensed medication or surgical procedure have been approved for NAFLD. 
Available rodent data is encouraging regarding the efficacy of fish derived n-3 fatty acids 
(eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) in NAFLD [7], regulating 
lipogenesis and fatty acid oxidation (via Srebp-1c and Ppara, respectively) [8]. However, in 
human randomised controlled trials (RCT), fish oil supplementation has shown mixed 
findings [9], with largely marginal effects on histologically defined NAFLD [10] and no impact 
on insulin action.  Flavan-3-ols (FLAV), a class of plant bioactive flavonoid compounds found 
in cocoa, tea and berries, are also emerging as a dietary strategy for NAFLD prevention, 
with efficacy attributed to their insulin sensitising, indirect antioxidant and anti-inflammatory 
effects [11].    
Despite the complexity of the NAFLD patho-physiology, to date dietary strategies which 
target NAFLD have taken a reductionist approach, examining the impact of single 
interventions. Here, based on their likely complementarity molecular targets, we examined 
for the first time the combined effect of n-3 and FLAV on NAFLD development using a high-
fat high-fructose (HF/HFr) mouse model. NAFLD severity was established by human 
histological NAFLD activity scoring (NAS) of the hepatic tissue, with insulin sensitivity 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
4 
 
assessed by intra-peritoneal glucose tolerance testing, targeted gene expression profiling 
and biochemical analyses performed in order to gain a mechanistic insight.  
 
2. MATERIALS AND METHODS 
2.1 Study approval 
All experimental procedures and protocols used in this study were reviewed and approved 
by the Animal Welfare and Ethical Review Body (AWERB) and were conducted within the 
provisions of the Animals (Scientific Procedures) Act 1986 (ASPA). 
 
2.2 Animal experimental design and dietary treatments 
Male C57BL/6J mice aged 4 weeks (n=50, Charles River Laboratories (Margate, UK) were 
maintained in 12 h light/dark cycle, under conditions of constant temperature (21 ± 2 °C) and 
humidity (55 ± 10%). After feeding a standard RM3 diet (Special Diet Services, Essex, UK) 
for two weeks, mice were assigned to five experimental groups (n=10 per group) and 
allowed free access to a control diet (C), high fat/high fructose (HF/HFr) diet, or a HF/HFr 
diet supplemented with cocoa powder (HF/HFr + FLAV, Chococru®, London, UK), fish oil 
(HF/HFr + n-3; EPAX, Oslo, Norway) or a combination of both (HF/HFr + FLAVn-3) 
(Research Diet Inc., New Brunswick, USA) for 16 weeks (Supplementary Table S1-S3). 
The FLAV and n-3 supplemented diets contained 667 µg/g cocoa flavan-3-ol monomers 
(epicatechin and catechin), and 6.67 mg EPA+DHA/g, which provided the animals with daily 
doses of 60, 7, 400 and 280 mg/kg body weight of (-)-epicatechin, (+)-catechin, EPA and of 
DHA respectively. Using allometric scaling this equated to physiologically relevant human 
(60 Kg body weight) equivalent doses (HED) of 255mg of epicatechin, 30mg catechin, 1.7g 
EPA and 1.2g DHA per day [12], which are the levels found in 30 g of FLAV-rich cocoa [13] 
and one large portion of oily fish [14], respectively. Food intake was assessed twice a week 
and food pellets were replaced every other day to avoid oxidation of the bioactive 
components. At week 16, animals were sedated and blood was collected by cardiac 
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puncture followed by trans-cardiac perfusion of ice-cold saline containing heparin (10 
units/ml). Plasma/serum samples were isolated by centrifugation at 2000 x g for 10 min and 
samples were snap-frozen and stored at -80° C. Livers were rapidly removed, rinsed with 
ice-cold NaCl (150 mmol/L), blotted and weighed. A lobe from each liver was preserved in 
formalin for histological analyses, and the remainder anatomical lobes were either snap-
frozen in liquid nitrogen or transferred into an RNA preservation solution (Qiagen, 
Manchester, UK) for gene expression analysis. 
 
2.3 Intra-peritoneal glucose tolerance test  
At the end of week 15, mice were fasted for 16 hours before being administered D-glucose 
(Sigma-Aldrich, Poole, UK) by intraperitoneal injection (2g/Kg body weight). Blood glucose 
was measured at 0, 10, 20, 30, 60 and 120 min using a AlphaTRAK 2 glucometer (Abbott 
Laboratories Ltd., Maidenhead, UK). Additional blood samples (20μl) were collected at 
baseline, 15 and 120 min into EDTA coated microvette tubes (Sarstedt Ltd., Leicester, UK), 
and concentrations of insulin were determined using a commercial ELISA kit (Crystal-Chem, 
Downers Grove, US). Insulin resistance was estimated by the homeostasis model 
assessment method (HOMA) [fasting plasma insulin (mU/ml) × fasting plasma glucose 
(mM)/22.5] [15]. 
 
2.4 Histological and Biochemical analyses 
Formalin-fixed murine liver specimens were processed for hematoxylin and eosin (H&E) 
staining as described previously [16]. The severity of liver disease was evaluated 
histologically by two blinded histopathologists, using the NAS scoring system, which is the 
standard system for reporting the extent of damage in human biopsy samples [17] and 
represents the combined semi-quantitated pathology score for steatosis (graded 0-3), lobular 
inflammation (graded 0-3), and hepatocyte ballooning (graded 0-2) and ranges from 0-8 [18]. 
NAS was calculated for each rodent group. Total lipids were extracted from 500 mg of food 
pellets or from 300 mg of liver with chloroform/methanol (2:1 v/v) and fatty acids were 
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analysed as reported previously [19]. The triglyceride content of the livers was carried out 
using the triglycerides Liquicolor® reagent (Cambridge Life Sciences Ltd, Ely, UK) following 
the manufacturer’s instructions. Lipid peroxidation end-products (LPO) were measured in 
liver homogenates with a colorimetric assay (Oxford Biomedical Research, Upper-Heyford, 
UK). AST, ALT and creatinine were quantified using commercially available kits (Werfen, 
Warrington, UK) on a clinical chemistry analyser IL650. Plasma leptin was measured using 
the Procarta mouse simplex immunoassay kit (Affymetrix eBioscience, Austria).  
 
2.5 Taqman Low Density Array (TLDA), qRT-PCR  
TLDA analysis was carried out on [20] samples from each of the 5 study groups (150ng 
RNA/TLDA port). Validation of the TLDA data by qRT-PCR was performed on an ABI prism 
7500 detection system (Applied Biosystems) as previously described [21] with primer probe 
sets from Applied Biosystem (Supplementary Table S4a and Table S4b). 
 
2.6 Flavan-3-ol metabolites and bile acids analyses 
Frozen liver samples (500mg) were lyophilized and ground before being processed 
according to Bresciani et al [22]. Briefly, proteins from tissue samples were precipitated with 
400 μL 20% (v:v) TCA and then extracted with 3 mL of cold methanol. The samples were 
vortexed vigorously for 5 min, placed in a sonicator bath for 5 min, and then centrifuged 
(4,000 g for 5 min). A second extraction was performed for each sample with 3 mL methanol 
as described above. The two supernatants were pooled and dried under vacuum by rotary 
evaporation. Finally, the pellet was suspended in 150 μL of 50% (v:v) methanol acidified with 
1% (v:v) formic acid. Urine samples were defrosted, centrifuged for 5 min at 8,765g, and 
diluted 1:4 with water containing 0.1% formic acid before analysis. 
Flavanol, procyanidin content (by degree of polymerization 1-10) and xanthines (caffeine 
and theobromine) of the cocoa powder wer analysed following published AOAC methods 
[23, 24]. Flavan-3-ol metabolites in liver and urine samples were analysed using ultra-high 
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performance liquid chromatography coupled with mass spectrometry (UHPLC-MS/MS) using 
an UHPLC DIONEX Ultimate 3000 equipped with a TSQ Vantage triple quadrupole mass 
spectrometer (Thermo Fisher Scientific Inc., San Jose, CA, USA) fitted with a heated-
electrospray ionization source (H-ESI; Thermo Fisher Scientific Inc.). For UHPLC, mobile 
phase A was 0.5% formic acid in water and mobile phase B was acetonitrile containing 0.5% 
formic acid. Separations were performed with a Kinetex PFP (50 × 2.1 mm) column, 2.6 μm 
particle size (Phenomenex, Macclesfield, UK). The gradient started with 1%B, keeping 
isocratic conditions for 1 min, reaching 40%B at 15 min, followed by 2 min at 80% B and 
then 4 min at the start conditions to re-equilibrate the column. The flow rate was set at 0.3 
mL/min, the injection volume was 5 μL, and the column was thermostated at 35°C. The 
applied method consisted in the selective determination of each target precursor ion by the 
acquisition of characteristic product ions in the “selected reaction monitoring” (SRM) mode, 
with negative ionization. The MS worked with capillary temperature at 270 °C, while the 
source at 200 °C. The sheath gas flow was 50 units, while auxiliary gas pressure was set to 
5 units. The source voltage was 3 kV. Ultra-high purity argon gas was used for collision-
induced dissociation (CID). Data processing was performed using Xcalibur software from 
Thermo Scientific. Most of the compounds were quantified by comparison with their 
corresponding standards; while 5-(3'-hydroxy-phenyl)valeric acid-sulfate, dihydroxyphenyl γ 
valerolactone-sulfates, and trihydroxyphenyl-y-valerolactone-sulfate,  were quantified as 3’-
hydroxyphenyl-γ-valerolactone (M7)-sulfate; (epi)catechin-sulfate, methyl-(epi)catechin-
sulfates, and (epi)gallocatechin-sulfate, as quercetin-sulfate; dihydroxyphenyl-valerolactone-
glucuronide and dihydroxyphenyl-valerolactone-sulfate-glucuronide as 3’-hydroxyphenyl-γ-
valerolactone (M7)-glucuronide; and (epi)catechin-glucuronide, methyl-(epi)catechin-
glucuronide, and (epi)catechin-sulfate-glucuronide as quercetin-glucuronide. Urinary 
excretion of selected metabolites was adjusted for creatinine levels. 
The concentration of bile acids in intestinal mucosa samples was analyzed by using an 
UPLC-H I-Class (Waters, UK) coupled to a Xevo-G2 QTof mass spectrometer (Waters, UK). 
Electrospray ionization was performed in the negative ionization mode. Chromatographic 
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separation was performed on a BEH C18 column (2.1 x 100 mm, 1.7 µm). The mobile phase 
consisted of water (Eluent A) and acetonitrile (Eluent B) both containing 0.1 % formic acid. 
Analytes were separated by a linear gradient elution. The injection volume was 2 µL and the 
column was maintained at 40 °C. Detection of the bile acids and their glycine and taurine 
conjugates was performed by exact mass (+/- 0.01 Da). All standards as well as the 
deuterated internal standard (IS) substance (d4-chenodeoxycholic acid) were purchased 
from Steraloids (Newport, USA). 
 
2.7 Statistics 
The impact of treatment was compared by one-way ANOVA followed by protected multiple 
comparison tests (i.e., Bonferroni and Tukey-Kramer) or Kruskal-Wallis followed by Dunn’s 
Multiple Comparison Test. Histology data and components of the NAS (steatosis amount, 
lobular inflammation, and ballooning) were analysed using a Mann-Whitney U test. For the 
IPGTT data, a repeated measures ANOVA was conducted with time and dietary groups as 
independent variables. One-way ANOVA with Duncan’s post hoc test was applied to 
compare values relating to tissue accumulation or urinary excretion of flavan-3-ol 
metabolites. When flavan-3-ol metabolites were detected only for the HF/HFr + FLAV and 
HF/HFr + FLAVn-3 groups, a t-test instead of one-way ANOVA was applied. For all tests, the 
bilateral alpha risk was set as α = 0.05. Principal component analysis (PCA) with varimax 
was also performed. The statistical analysis was conducted using the SPSS package 
(version 16.0; SPSS Inc., Chicago, IL, USA). 
 
3. RESULTS 
3.1 Flavan-3-ols and n-3 fatty acids supplemented diets protect the liver from 
developing the biochemical and histological features of NASH 
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Following 16 weeks of HF/HFr feeding, mice developed steatosis and hepatocyte ballooning, 
while livers from control-fed mice showed normal histological hepatocyte architecture and no 
evidence of steatosis (Figure 1A). Mice fed with FLAV and n-3 displayed a reduction in the 
lipid droplet size and hepatocyte damage induced by HF/HFr. Upon conversion of the 
histological images into semi-quantitative data, relative to HF/HFr, FLAVn-3 supplementation 
significantly decreased both steatosis and hepatocyte ballooning (Table 1). Reduction in 
hepatocyte ballooning was also observed in presence of n-3 also, but to a lesser extent. 
Fatty liver development and liver function was also assessed by liver TAG and serum ALT 
and AST. Consistent with the histology, HF/HFr was associated with significant increases in 
all three markers (Figure 1B-D), which were ameliorated by FLAV and n-3 supplementation. 
 
3.2 The weight gain associated with HF/HFr feeding is in part negated by flavan-3-ol 
supplementation  
At 16 weeks, body weight gain and liver weight were 50% and 33% higher respectively in the 
HF/HFr mice compared to the control animals (Figure 2A and Figure 2B). FLAV and 
FLAVn-3 supplementation reduced weight gain by 28-30% with no differences in body 
weight associated with n-3 supplementation. No difference in cumulative food intake 
between groups was evident (average 2.55 ± 0.08 g/d, data not shown). A 4-fold increase in 
inguinal adipose tissue mass (Figure 2C) along with a 10-fold higher plasma leptin levels 
(Figure 2D) were also observed in mice fed a HF/HFr relative to control diet. Such increased 
levels were partly attenuated by FLAV and FLAVn-3 feeding (Figure 2C-D). 
 
3.3 Flavan-3-ol but not n-3 maintains insulin sensitivity in fed mice challenged with a 
HF/HFr diet 
HF/HFr diet raised fasted blood glucose, plasma insulin and HOMA-IR relative to control, 
indicative of decreased insulin sensitivity (Figure 3A-C). In the IPGTT, HF/HFr feeding 
raised glucose concentrations at 60 and 120 min relative to control (Figure 3A). For insulin, 
2- and 3-fold higher concentrations were observed at 15 min and 120 min respectively in the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
10 
 
HF/HFr group (Figure 3B). At 120 min, FLAV and FLAVn-3 reduced insulin levels by 35% 
indicative of a FLAV associated amelioration of the loss of insulin sensitivity induced by 
HF/HFr. Additionally, only the FLAVn-3 supplementation decreased HOMA-IR. (Figure 3C). 
 
3.4 Supplementation with n-3 fatty acids and flavan-3-ols modulates the expression of 
genes involved in hepatic lipid accumulation and fibrosis. 
HF/HFr upregulated genes associated with hepatic lipid accumulation with an almost 2-fold 
increase in the expression of the lipogenic genes, acyl-CoA carboxylase (Acaca) and fatty 
acid synthase (Fasn). Likewise, 1.5-6 fold increases in the fatty acid/lipoprotein receptors, 
fatty acid binding protein 4 (Fabp4) and very-low-density-lipoprotein receptor (Vldlr) were 
evident, along with an up-regulation of sterol regulatory element-binding protein 1c (Srebf1), 
the main transcription factor modulating lipogenesis (Acaca and Fasn). n-3 (+/- FLAV) 
decreased Acaca, Fasn and Srebf1 expression with FLAV (+/- n-3) down-regulating Fabp4 
and the Vldlr expression. Although no impact of HF/HFr feeding on fibrosis-related genes 
was observed, FLAV and n-3 down-regulated collagen 1A1 (Col1a1), Col1a2, matrix 
metalloproteinase (Mmp) 2, and tissue inhibitor of MMP 2 (Timp2), with an increase in Timp3 
evident following combined FLAVn-3 exposure (Figure 4 and Supplementary Table S5). 
 
3.5 Flavan-3-ols but not n-3 fatty acids alter bile acid metabolism leading to 
upregulation of CYP7A1 in mice fed a HF/HFr diet 
HF/HFr diet had a negligible impact on total illeal bile acids (Figure 5A), with a modest 
increase in the proportion in the conjugated form (Figure 5B). Supplementing HF/HFr with 
FLAV alone or in combination with n-3 not only enhanced the percentage of conjugated 
forms (Figure 5B) but also reduced the content of hyodeoxycholic acid (HDCA) (Figure 5C), 
decreased the ratio HDCA to muricholic acids (MCA) (Figure 5D), increased the level of 
FXR-agonist bile acids and tended to increase the content of FXR-antagonist species 
(Figure 4E). The magnitude of these widespread effects were most pronounced for FLAVn-
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3. Although statistically not significant, it is important to note that the balance of FXR bile 
acid activators and inhibitors was about 40% more antagonistic in mice fed FLAV, n-3, and 
FLAVn-3 than in their counterparts offered HF/HFr and control diet. Compared to HF/HFr, all 
treatments decreased FXR signalling as revealed by a downregulation of Shp mRNA in the 
ileum and liver (Figure 6A, D). The greatest inhibitory action was evident with FLAV, which 
is consistent with the response to intervention of other FXR target genes in the liver (Cyp7a1 
and Cyp8b1, Figure 6B, C) and the intestine (Tgr5 and Gcg, Figure 6E, F) and Fgf15 
(Supplementary Figure S1).  
 
3.6 Supplementation with n-3 fatty acids and flavan-3-ols results in significant 
increases in hepatic tissue EPA, DHA and flavan-3-ol metabolite concentrations 
In the n-3 groups a 1.7 and 4.0 absolute increase in percentage EPA and DHA was evident 
relative to the HF/HFr, with no impact of FLAV on fatty acid status (Supplementary Table 
S6). Furthermore, n-3 feeding increased tissue lipid hydroperoxide (LPO) levels by 
approximately 2-fold relative to the other groups. 
Potential flavan-3-ols metabolites were monitored using LC-MS methods with five microbial 
FLAV degradation products [25] detected in the liver samples (Supplementary Table S7 
and S8). In particular, a significant increase in hydroxyphenylvalerolactones, originating from 
the C-ring-opening of flavan-3-ols by the colonic microflora followed by further lactonization, 
was observed. In addition, urine samples were analysed and 37 compounds identified, 
including phase II and colonic metabolites which varied significantly between groups 
(Supplementary Table S9). n-3 fatty acid consumption modified the metabolism of flavan-3-
ols, enhancing the excretion of phase II conjugates of flavan-3-ol monomers and 
hydroxyphenylvalerolactones while decreasing the excretion of phenolic acid conjugates 
which is suggestive of enhanced FLAV absorption (Supplementary Table S9, Figure S2 
and Figure S3). 
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4. Discussion 
Liver disease is the third most common cause of premature death in the UK [26]. Due to the 
increased incidence of obesity, NAFLD is now more prevalent than alcohol-induced liver 
disease [2] with 67% of overweight and 94% of obese individuals presenting this condition 
[27]. The HF/HFr regime was selected as a physiologically relevant model for human NAFLD 
development and resulted in steatosis and hepatocyte ballooning indicative of early NASH. 
In this study we demonstrate that combined supplementation with FLAVn-3 prevented 
steatosis and hepatocyte ballooning, lowered weight and adipose tissue gain and improved 
insulin sensitivity. Our findings are similar to previous data demonstrating that 8% cocoa 
powder for 10 weeks significantly reduced the rate of body weight gain, as well as final body 
weight and retroperitoneal WAT weight compared to HFD-fed controls [28]. Such effects 
may be related to increased faecal fat excretion [29], with cocoa extracts and their 
component polyphenols shown to inhibit the activity of pancreatic lipase and secreted 
phospholipase A2, which may reduce dietary fat absorption [30]. Individual feeding of FLAV 
and n-3 identified numerous physiological and molecular mechanisms which are likely to 
have acted synergistically to prevent NASH in the FLAVn-3 group. Previous studies have 
reported the hypoglycemic and insulin sensitising effects of cocoa polyphenols. For example, 
a proanthocyanidin-rich cocoa liquor extract suppressed a HFD-induced hyperglycemia 
through the activation of AMP-activated protein kinase α, and the translocation of glucose 
transporter 4 in mice [20]. In addition, short-term administration of dark chocolate improved 
insulin resistance in terms of improved HOMA-IR and quantitative insulin sensitivity check 
index (QUICKI) in healthy subjects [31]. Whilst cocoa polyphenols may play a large part in 
the observed effects, emerging evidence is also suggestive that caffeine contribute to the 
weight loss [32] although its intake could explain some but not all of the diabetes-risk 
reduction and weight change in humans [33]. In this study, FLAV ameliorated the HF/HFr 
induced obesity, the aetiology of which is likely related to changes in bile acid metabolism 
[34]. Whilst most bile acids enter the gut conjugated to taurine or glycine, these are 
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deamidated by microbial bile salt hydrolases (BSH) in the distal small intestine and, if not 
absorbed and transported back to the liver, are further metabolized by gut microbiota [35]. 
Recent studies in obese mice showed that partial inhibition of BSH by antibiotics [36] results 
in the intestinal accumulation of conjugated bile acids, and in particular of the FXR 
antagonists tauro-muricholic acid (T-MCA) [37] and tauro-ursodeoxycholic acid (TUDCA) 
[38], therefore reducing steatosis and body weight gain partly via repressed expression of 
hepatic Srebf1 [36]. Recent evidence suggest that elevated FXR antagonistic bile acids 
along with FXR antagonist that specifically inhibit intestine FXR, play a role in the treatment 
of NAFLD [39]. The role of intestinal FXR in body weight reduction, insulin resistance and 
fatty livers was firmly established in mice lacking FXR that are metabolicaly resistant to HFD-
induced metabolic disease [40]. Furthermore, liver-specific Shp deletion, a target of FXR, 
prevented hepatic steatosis in animal fed a HFD and Western diet whilst the global double 
knockdown of Shp and Fxr protected against weight gain, glucose intolerance and hepatic 
steatosis [41]. Accordingly, our results indicate that FLAV, and in particular when combined 
with n-3, partially suppressed bile salt deconjugation and the subsequent microbial 
conversion of MCA into HDCA resulting in an increase of FXR bile acids antagonist which 
favoured its signalling inhibition in the intestine and liver. More precisely, we demonstrate 
that the FLAV-triggered repression of hepatic Shp translated into enhanced expression of 
Cyp7a1, the rate-limiting enzyme in the bile acid synthesis pathway, whose overexpression 
in the liver of mice counteracted diet-induced obesity, steatosis, and insulin resistance [42]. 
In support of this statement, the finding that FLAV suppressed the expression of Tgr5 and 
Gcg mRNA levels in the small intestine, suggests that the secretion of glucagon-like peptide-
1 via intestinal Tgr5 did not account for the metabolic improvements caused by FLAV. 
Additionally, FLAV resulted in lower fasting insulin and insulin concentrations following the 
IPGTT, which along with the increased expression of Cyp7a1 is thought to underlie the 
impact on steatosis and hepatocyte ballooning evident following the FLAVn-3 treatment.  
Given the collinearity between the FLAV induced changes in weight and insulin responses, 
the weight independent influence of FLAV on insulin sensitivity and NASH development 
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cannot be established. The weight gain associated with HF/HFr was accompanied by 
elevated plasma leptin. Leptin is secreted in proportion to white adipose tissue mass and is 
essential in the regulation of energy homeostasis, glucose and lipid metabolism functions 
[43]. The role of leptin in the progression of NAFLD remains unknown, but clinical data 
summarised in a meta-analysis (evaluating 33 studies and 2612 individuals), reported that 
circulatory leptin levels were associated with the severity of NAFLD [44]. Obesity is 
commonly associated with hyperleptinemia that can progress to leptin resistance with 
attenuated hypothalamic leptin signalling which fails to reduce the excess of adiposity [45, 
46]. Here we showed that Flavn-3 reduced the weight gain induced by the HF/HFr diet, and 
was associated with lower circulating leptin levels, which may suggest improved leptin 
signalling. In agreement with this observation. In agreement with this observation and our 
FLAV induced lowering of leptin concentrations, Park et al. [47] recently reported that a 
flavonoid-rich grape extract reduced leptin, which together with our results suggest that 
altered leptin metabolism may partly underlie the FLAV induced reduction in NAFLD. These 
novel findings expand the state-of-the-art regarding the mechanism underlying the benefits 
of flavonoids in NAFLD [11]. 
De novo lipogenesis has been approximated to be 5-fold greater in NAFLD compared to 
normal individuals [48]. Our gene expression profiles indicate that reduced lipogenesis due 
to lower Acaca and Fasn expression along with their regulatory transcription factor Srebf1 
underlies the observed n-3 induced reduced steatosis, which is consistent with previous 
observations [49, 50]. A significant reduction in Nr1h3, the gene encoding the liver X 
receptor alpha (Lxra), a Sreb1f upstream regulator, induced by n-3 supports this observation 
(See Supplementary Table S4). No significant impact of treatment on carnitine 
palmitoyltransferase I (Cpt1) was evident, indicating that increased mitochondrial fatty acid 
oxidation did not significantly contribute to the reduced steatosis. Increased fatty acid flux 
from adipose tissue and uptake of fatty acids as lipoproteins or complexed to albumin also 
contributes to hepatic TAG load in NAFLD. In particular, the lipoprotein and fatty acid 
receptors Vldlr and Fabp4 have been implicated in NAFLD progression [51]. The observed 
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reduced expression of these receptors following both n-3 and FLAV supplementation is also 
likely to significantly contribute to the reduced steatosis and TAG concentration observed. Of 
interest is that because FLAV, but not n-3, failed to reduce the expression of Srebf1, a target 
gene of Fxr that controls fatty acid synthesis [52], such an explanation could also account for 
the synergistic effect of combining FLAV with n-3 in preventing NALFD development.  
Finally, although not evident in the liver, an n-3 induced increase in the apparent 
bioavailability (based on higher urinary excretion) of select flavan-3-ol metabolites was 
observed which could contribute to the greater efficacy of FLAVn-3 relative to FLAV alone. 
This finding is consistent with Giunta et al. [53] who observed an n-3 induced increase in 
blood and brain green tea flavonoid concentrations in mice.  
 
In conclusion combined supplementation with FLAVn-3 is highly effective in preventing 
NAFLD. The additive anti-lipogenic (n-3 effect) and insulin sensitising actions associated 
with reduced weight gain (FLAV effect) is likely to be responsible for the greater effects 
relative to either dietary component fed in isolation (Figure 6). The ability of this combined 
dietary approach to reverse steatosis or the more pathological NASH and fibrosis stages of 
the disease remains to be established and should be explored in clinical trials. 
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Figure legends 
Figure 1. Hepatic biochemical and histological evidence of steatohepatitis in the liver 
of mice fed with a high fat/high fructose diet and the amelioration induced by the 
individual and combined impact of 16 weeks intervention with flavan-3-ols and n-3 
fatty acids. A) Representative H&E-stained images of liver from mice fed with the different 
diets under 20x magnification. B) Liver TAG; C) Serum ALT; D) Serum AST. Values are 
expressed as mean ± SEM. n ≥ 7 (per group). Different superscripts indicate statistical 
differences between diet groups, **p < 0.01; ***p < 0.001; vs the control group. NS, not 
significant 
 
Figure 2. Effect of flavan-3-ols and n-3 fatty acids on body weight gain, liver and 
adipose tissue weight and leptin levels in mice fed a high fat/high fructose diet. (A) 
Body weight gain (0-16 weeks). (B) Liver weight (C) Inguinal adipose tissue weight (D) 
Plasma leptin (16 weeks). Values are expressed as mean ± SEM. n ≥ 7 (per group). 
Different superscripts indicate statistical differences between diet groups. 
Figure 3. Effect of flavan-3-ols and n-3 fatty acids on insulin and glucose response in 
mice fed a high fat/high fructose diet. (A) Glucose and (B) insulin concentrations during 
the intraperitoneal glucose tolerance test (15 weeks). (C) Homeostatic model assessment for 
insulin resistance (HOMA-IR) (15 weeks). Values are expressed as mean ± SEM. n ≥ 7 (per 
group). Different superscripts indicate statistical differences between diet groups, *p < 0.05; 
**p < 0.01; ***p < 0.001; vs the control group. # depicts statistical significance (p < 0.05) 
when compared to the control group (fasted state). 
Figure 4. Taqman Low Density Array (TLDA) and real time quantitative PCR (qRT-PCR) 
analysis of liver samples. Impact of the intervention treatments on the gene expression 
modulation of A) Fatty acid uptake, B) Lipogenesis and C) Fibrosis. Values are expressed as 
mean ± SEM. n ≥ 7 (per group). Different superscripts indicate statistical differences 
between diet groups. 
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Figure 5. Flavan-3-ols and n-3 fatty acids alter intestinal bile acid metabolism and 
signature in mice fed a high fat/high fructose diet. Concentration of (A) total bile acids; 
(B) proportion of conjugated bile acids; (C) content of hyodeoxycholic acid (HDCA); (D) ratio 
HDCA to tauro-muricholic acids (αMCA + βMCA); and (E) concentration of FXR bile acid 
activators or inhibitors in the small intestine. Values are least square means ± SEM, n = 7-8 
per treatment. Different superscripts indicate statistical differences between diet groups, P < 
0.001. CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; T-UDCA, 
tauro ursodeoxycholic acid.  
 
Figure 6. Flavan-3-ols and n-3 fatty acids inhibit FXR signalling in the intestine and 
liver of mice fed a high fat/high fructose diet. Gene expression of FXR target genes in 
the liver (A-C) and illeum (D-F). Values are expressed as mean ± SEM. n ≥ 7 (per group). 
Different superscripts indicate statistical differences between diet groups, P < 0.05. Shp, 
small herodimer partner; Cyp, cytochrome P450; Tgr5 (aka Gpbar1, G protein-coupled bile 
acid receptor 1); Gcg, glucagon. 
 
Figure 7. Proposed mechanisms underlying the effect of flavan-3-ols (FLAV), n-3 fatty 
acids (n-3) and their combination (FLAVn-3) in NAFLD prevention. a) n-3 increases the 
bioavailability of FLAV in the intestine. b) FLAV increase the pool of Fxr bile acids (BA) 
antagonists which reduce its downstream effector (SHP) and in turn upregulates Cyp7a1. c) 
FLAV and/or its metabolites reduce the higher insulin and leptin plasma levels and d) 
overweight induced by HF/HFr diet. e) n-3 supresses TAG accumulation in the liver by 
downregulating de novo lipogenesis (DNL). f) FLAVn-3 reduces the fatty acids efflux into the 
liver through downregulation of lipoprotein (VLDLr) and fatty acids receptors (FABP4). g) 
FLAVn-3 downregulates genes involved in fibrosis (FIBR).   
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Table 1. Histological changes following 16 weeks high fat high fructose (HF/HFr) diet 
supplemented or not with flavanols (FLAV), long-chain n-3 PUFAs (n-3) or a combination of 
both (FLAVn-3). Components of the NAS (steatosis amount, lobular inflammation, and 
ballooning) mean scores are expressed as mean ± standard deviation and significance was 
obtained using the Mann-Whitney U test for P<0.05.  
 
 Control HF/HFr HF/HFr 
   + Flav + n-3 + FLAVn-3 
Steatosis      
Grade 0 (< 5 %) 7 3 7 8 9 
Grade 1 (5-33 %) 0 3 2 2 1 
Grade 2 (34-66 %) 0 4 0 0 0 
Grade 3 (>66 %) 0 0 0 0 0 
Mean Score  0.0 ± 0.0b 1.1 ± 0.8a  0.2 ± 0.4ab 0.2 ± 0.2ab 0.1 ± 0.3b 
      
Lobular Inflammation      
Grade 0 (none) 5 1 5 6 8 
Grade 1 (<2) 2 9 4 4 2 
Grade 2 (2-4) 0 0 0 0 0 
Grade 3 (>4) 0 0 0 0 0 
Mean Score 0.2 ± 0.4 0.6 ± 0.3 0.3 ± 0.4 0.3 ± 0.3 0.3 ± 0.5 
      
Hepatocyte Ballooning      
Grade 0 (none) 7 1 5 8 10 
Grade 1 (few) 0 2 3 2 0 
Grade 2 (many) 0 7 1 0 0 
Mean Score 0.0 ± 0.0b 1.6 ± 0.7a 0.6 ± 0.7ab 0.2 ± 0.2b 0.0 ± 0.0b 
      
NAS Score (0-8) 0.2 ± 0.2b 3.3 ± 0.5a 1.1 ± 0.2b 0.7 ± 0.1b 0.4 ± 0.2b 
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Highlights 
 Although highly prevalent, no treatment exists for NAFLD 
 Flavonoids (FLAV) and n-3 fatty acids are emerging as dietary strategies 
 FLAV and n-3 reduced steatosis, body weight gain and insulin resistance in mice 
 FLAV ameliorated bile acid metabolism and n-3 downregulated lipogenic genes 
 FLAVn-3 should be tested for efficacy in human NAFLD 
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